Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

Supporting Information

Pyrazole based palladacycle for the synthesis of βaminoketones by redox coupling of allyl alcohols and anilines

Shaikh Samser, Priyabrata Biswal, Ramesh Mamidala, Sushanta Kumar Meher and Krishnan Venkatasubbaiah*

School of Chemical Sciences, National Institute of Science Education and Research (NISER), Bhubaneswar, an OCC of Homi Bhabha National Institute Bhubaneswar-752050, Odisha, India. E-mail: <u>krishv@niser.ac.in</u>

Table of Contents

General information	• S2
General experimental procedure	• S2
Synthesis of BINOL phosphoric acid	. S2
Synthesis of Palladacycle II	. S2
Synthesis of Palladacycle III	. S3
Experimental procedure for controlled reactions	• S4
Analytical data for β-amino products	. S4
NMR spectra of all compounds	. S 9
Crystal data of palladacycle II and III	S36
Molecular structure of palladacycle II	• S37
Molecular structure of palladacycle III	S38
References	S39

General Information: All chemicals were used as received from commercially available sources such as Sigma-Aldrich, Alfa-aesar, TCI, and Spectrochem, and used without further purification. 1,2-dichloroethane was distilled from CaH₂. THF was distilled from Na/Benzophenone prior to use. All reactions were carried out in open air unless notified. NMR spectra were recorded on Bruker ARX 400 and Bruker Advance 700 spectrometer at room temperature. ¹H (400 MHz or 700MHz) and ¹³C (100 MHz or 176MHz) NMR chemical shifts in ppm were referenced internally to its proton resonance of incomplete deuterated solvent signals. ³¹P NMR (81 MHz) spectra were externally reference to H₃PO₄ in D₂O ($\delta = 0$). High-resolution mass spectra (HRMS) were recorded on a Bruker microTOF-QII mass spectrometer.

General procedure for synthesis of β -aminoketones: To a screw cap scintillation vial aryl amine (0.5 mmol), allyl alcohol (2.0 mmol), catalyst (0.0125 mmol) and BINOL phosphoric acid (0.025 mmol) were charged in open air and 1 mL DCE was added to it. The reaction mixture was allowed to stir at room temperature for 48 hours. The reaction mixture was diluted with dichloromethane (3 x 5 mL), and concentrated under vacuum. The crude mixture was subjected to column chromatography on silica gel using ethyl acetate and n-hexanes mixtures to afford the β -aminoketones as pure product.

Synthesis of BINOL phosphoric acid: (S)-BINOL (1.0 g, 3.5 mmol) was dissolved in pyridine (10 mL). Phosphorous oxychloride (0.65 mL, 7 mmol) was added dropwise at room temperature with rapid stirring and the resulting solution was stirred at 60 °C for 12 hours. Water (10 mL) was added and the resulting biphasic suspension was stirred at 50 °C for a further 2 hours. The reaction mixture was diluted with CH_2Cl_2 and pyridine was extracted by washing with 1N HCl aq. The combined organic phase was dried over Na₂SO₄ and concentrated. The crude solid was purified by flash silica gel chromatography (5% MeOH in CH_2Cl_2) to yield the product as ivory-white solid (1.08g, 90%).

Synthesis of Palladacycle II (Scheme S1): Palladacycle I (1.0g, 0.83 mmol) was taken in a 100 mL Round bottomed flask and was dissolved in methanol. LiCl (0.35g, 8.3 mmol) was added to it and was stirred overnight at RT. Then, excess amount of water was added to it which resulted in precipitation. The reaction mixture was filtered and the residue was washed with excess water to remove any lithium salt. The residue was dried and dissolved in chloroform and was layered with hexane for crystallisation at low temperature. Yellow crystals were obtained in 88% (0.83g) yield. ¹H NMR (400 MHz, CDCl₃) δ 7.98 (s, 2H), 7.77 (s, 4H), 7.40 – 7.35 (m, 2H), 7.34 – 7.30 (m, 4H), 7.24 (dd, *J* = 7.4, 1.6 Hz, 2H), 7.11 (d, *J* = 6.9 Hz, 4H), 7.05 (t, *J* = 7.4 Hz, 2H), 6.83 (t, *J* = 7.7 Hz, 2H), 6.69 (d, *J* = 8.2 Hz, 2H), 6.67 (s, 2H). ¹⁹F decoupled ¹³C{¹H, ¹⁹F} NMR (101 MHz, CDCl₃) δ 160.97, 147.94, 144.58, 137.80, 136.08, 133.19, 132.95, 130.05, 129.22, 129.09, 129.05, 128.03, 127.26, 125.29, 123.65, 123.30, 102.38. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.72. Elemental analysis calcd (%) for C4₆H₂₆Cl₂F₁₂N₄Pd₂: C 48.19, H 2.29, N 4.89. Found: C 49.12, H 2.68, N 4.66. HRMS (ESI): calculated for C4₆H₂₆Cl₂F₁₂N₄Pd₂ ([M + H]⁺) : 1144.9656, found : 1144.9118.

Synthesis of Palladacycle III (Scheme S2): Palladacycle S2 (0.5g, 0.437 mmol) was dissolved in chloroform. Silver BINOL phosphate (0.39g, 0.874 mmol) was added to it. The reaction was ran for overnight with vigorous stirring. After a fast celite filtration, the solvent was evaporated under vacuum, yellow solid was obtained. The compound was dissolved in DME and layered with hexane for crystallisation at low temperature. Yellow crystals were obtained in 76% (0.58g) yield. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (dd, *J* = 16.2, 8.5 Hz, 4H), 7.81 (d, *J* = 8.1

Hz, 2H), 7.68 (d, J = 8.9 Hz, 2H), 7.50 – 7.41 (m, 8H), 7.40 – 7.35 (m, 7H), 7.35 – 7.33 (m, 3H), 7.32 (d, J = 2.7 Hz, 3H), 7.28 (d, J = 7.2 Hz, 4H), 7.25 – 7.22 (m, 5H), 7.18 (t, J = 7.2 Hz, 2H), 7.03 (t, J = 7.4 Hz, 2H), 6.92 (s, 2H), 6.90 – 6.86 (m, 4H), 6.40 (s, 2H). ¹⁹F decoupled ¹³C{¹H, ¹⁹F} NMR (101 MHz, CDCl₃) δ 160.25, 148.40, 147.80, 145.86, 143.83, 136.92, 136.04, 132.67, 132.19, 131.70, 131.48, 130.83, 130.41, 129.73, 129.13, 128.77, 128.50, 128.39, 127.52, 126.60, 126.16, 125.82, 125.67, 125.04, 124.64, 122.62, 122.16, 121.52, 121.11, 120.88, 103.08. ³¹P NMR (162 MHz, CDCl₃) δ 13.58. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.69, -62.70. Elemental analysis calcd (%) for C₈₆H₅₀F₁₂N₄O₈P₂Pd₂: C 58.35, H 2.85, N 3.17. Found: C 57.86, H 3.00, N 3.26. HRMS (ESI): calculated for C₈₆H₅₀F₁₂N₄O₈P₂Pd₂ ([M + H]⁺) : 1791.0878, found : 1791.0872.



Scheme S2



Experimental procedure for controlled reactions

Scheme 2.a

To a screw cap scintillation vial 1-penten-3-ol (0.172 g, 2.0 mmol), palladacycle **1** (0.0125 mmol), and BINOL phosphoric acid (0.025 mmol) were charged in open air and 1 mL of DCE was added to it. The reaction mixture was allowed to stir at room temperature for 24h. Crude reaction mixture was analysed for ¹H and ¹³C analysis.

Scheme 2.b

To a screw cap scintillation vial *p*-anisidine (0.061g, 0.5 mmol), 1-penten-3-one (0.168g ml, 2.0 mmol), palladacycle **1** (0.0125 mmol), and BINOL phosphoric acid (0.025 mmol) were charged in open air and 1 mL of DCE was added to it. The reaction mixture was allowed to stir at room temperature for 24h. The reaction mixture was diluted with dichloromethane (3 x 5 mL) and concentrated under vacuum. The crude mixture was subjected to column chromatography on silica gel using ethyl acetate and n-hexanes mixtures to afford the β -aminoketones as pure product.

Scheme 2.c

To a screw cap scintillation vial *p*-anisidine (0.061g, 0.5 mmol), pentan-3-one (0.172g, 2.0 mmol), palladacycle **1** (0.0125 mmol), and BINOL phosphoric acid (0.025 mmol) were charged in open air and 1 mL of DCE was added to it. The reaction mixture was allowed to stir at room temperature for 24h. The reaction mixture was monitored through TLC. No β -aminoketone product was observed.

Scheme 2.d.

To a screw cap scintillation vial *p*-anisidine (0.061g, 0.5 mmol), 1-penten-3-ol (0.172g, 2.0 mmol), and palladacycle **3** (0.022g, 0.0125 mmol) were charged in open air and 1 mL of DCE was added to it. The reaction mixture was allowed to stir at room temperature for 24h. The reaction mixture was diluted with dichloromethane (3 x 5 mL), and concentrated under vacuum. The crude mixture was subjected to column chromatography on silica gel using ethyl acetate and n-hexanes mixtures to afford the β -aminoketones (0.094g, 91%) as pure product.

Analytical data for β-aminoketones:

4-((4-methoxyphenyl)amino)butan-2-one (Table 2, product 1)¹ : prepared from *p*-anisidine (0.061g, 0.5 mmol) and 3-buten-2-ol (0.144g ml, 2.0 mmol). After purification by column chromatography, the compound was isolated as brown liquid (0.081g, 84%). ¹H NMR (400 MHz, CDCl₃) δ = 6.77 (d, *J* = 8.9, 2H), 6.59 (d, *J* = 8.9, 2H), 3.74 (s, 3H), 3.35 (t, *J*=6.1, 2H), 2.72 (t, *J*=6.1, 2H), 2.15 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) ¹³C NMR (101 MHz, CDCl₃) δ 208.32, 152.57, 141.81, 115.03, 114.84, 55.88, 42.72, 39.76, 30.38. HRMS (ESI): calculated for C₁₁H₁₅NO₂ ([M + H]⁺) : 194.1176, found : 194.1182

4-((2-methoxyphenyl)amino)butan-2-one (Table 2, product 2)² : prepared from *o*-anisidine (0.061g, 0.5 mmol) and 3-buten-2-ol (0.144g, 2.0 mmol). After purification by column chromatography, the compound was isolated as brown liquid (0.0878g, 91%). ¹H NMR (400 MHz, CDCl₃) δ 6.88 (t, *J* = 7.5 Hz, 1H), 6.78 (d, *J* = 7.7 Hz, 1H), 6.75 – 6.64 (m, 2H), 3.83 (s, 3H), 3.44 (t, *J* = 6.3 Hz, 2H), 2.80 (t, *J* = 6.3, 2H), 2.17 (s, 3H). ¹³C NMR (101 MHz, CDCl₃)) δ 207.87, 147.39, 137.32, 117.36, 110.43, 109.78, 55.55, 42.91, 38.56, 30.39. HRMS (ESI): calculated for C₁₁H₁₅NO₂ ([M + H]⁺) : 194.1176, found : 194.1202.

4-((3-methoxyphenyl)amino)butan-2-one (Table 2, product 3)¹ : prepared from *m*-anisidine (0.061g, 0.5 mmol) and 3-buten-2-ol (0.144g, 2.0 mmol). After purification by column chromatography, the compound was isolated as brown liquid (0.06g, 62%). ¹H NMR (400 MHz, CDCl₃) δ 7.07 (t, J = 8.1 Hz, 1H), 6.27 (d, J = 8.1Hz, 1H), 6.21 (d, J = 8.0 Hz, 1H), 6.15 (m, 1H), 3.76 (s, 3H), 3.39 (t, J = 6.1 Hz, 2H), 2.73 (t, J = 6.1 Hz, 2H), 2.15 (s, 3H)⁻¹³C NMR (101 MHz, CDCl₃) δ 208.23, 160.90, 149.15, 130.11, 106.16, 102.73, 98.99, 55.14, 42.59, 38.36, 30.35. HRMS (ESI): calculated for C₁₁H₁₅NO₂ ([M + H]⁺) : 194.1176, found : 194.1201

4-(phenylamino)butan-2-one (Table 2, product 4)¹ : prepared from aniline (0.046g, 0.5 mmol) and 3-buten-2-ol (0.144g, 2.0 mmol). After purification by column chromatography, the compound was isolated as brown liquid (0.052g, 64%). ¹H NMR (400 MHz, CDCl₃) δ 7.19 (t, *J* = 6.9 Hz, 2H), 6.73 (t, *J* = 8.0 Hz, 1H), 6.64 (d, *J* = 7.5 Hz, 2H), 3.41 (d, *J* = 8.2 Hz, 2H), 2.75 (t, *J* = 8.1 Hz, 2H), 2.16 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 208.19, 147.39, 129.47, 118.15, 113.46, 42.60, 38.77, 30.44. HRMS (ESI): calculated for C₁₀H₁₃NO ([M + H]⁺) : 164.1070, found : 164.1100

4-(p-tolylamino)butan-2-one (Table 2, product 5)¹ : prepared from *p*-toluidine (0.053g, 0.5 mmol) and 3-buten-2-ol (0.144g, 2.0 mmol). After purification by column chromatography, the compound was isolated as yellow liquid (0.065g, 74%). ¹H NMR (400 MHz, CDCl₃) δ = 6.99 (d, *J*=8.2, 2H), 6.55 (d, *J*=8.3, 2H), 3.39 (t, *J*=6.1, 2H), 2.74 (t, *J*=6.1, 2H), 2.23 (s, 3H), 2.16 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 208.35, 145.60, 129.95, 127.02, 113.45, 42.79, 38.93, 30.47, 20.54. HRMS (ESI): calculated for C₁₁H₁₅NO ([M+H]⁺): 178.1226, found: 178.1221

4-(o-tolylamino)butan-2-one (Table 2, product 6) : prepared from *o*- toluidine (0.053g, 0.5 mmol) and 3-buten-2-ol (0.144g, 2.0 mmol). After purification by column chromatography, the compound was isolated as yellow liquid (0.0788g, 89%). ¹H NMR (400 MHz, CDCl₃) δ 7.13 (t, *J* = 7.7 Hz, 1H), 7.06 (d, *J* = 7.2 Hz, 1H), 6.67 (t, *J* = 7.5 Hz, 1H), 6.63 (d, *J* = 8.0 Hz, 1H), 3.47 (t, *J* = 6.1 Hz, 2H), 2.79 (t, *J* = 6.1 Hz, 2H), 2.17 (s, 3H), 2.12 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 208.30, 145.68, 130.35, 127.16, 122.66, 117.30, 109.75, 77.48, 77.16, 76.84, 42.65, 38.44, 30.38, 17.51. HRMS (ESI): calculated for C₁₁H₁₅NO ([M + H]⁺): 178.1226, found: 178.1254.

4-((4-(trifluoromethyl)phenyl)amino)butan-2-one (Table 2, product 7) : prepared from 4-(trifluoromethyl)aniline (0.080g, 0.5 mmol) and 3-buten-2-ol (0.144g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellowish white solid (0.1098g, 95%). ¹H NMR (400 MHz, CDCl₃) δ = 7.40 (d, *J*=8.5, 2H), 6.62 (d, *J*=8.5, 2H), 3.45 (t, *J*=6.0, 2H), 2.77 (t, *J*=6.0, 2H), 2.18 (s, 3H). ¹⁹F decoupled ¹³C NMR (101 MHz, CDCl₃) δ 207.94, 150.33, 126.71, 118.85, 111.97, 42.26, 37.82, 30.29. HRMS (ESI): calculated for C₁₁H₁₂F₃NO ([M + H]⁺) : 232.0944, found : 232.0958

1-((4-methoxyphenyl)amino)pentan-3-one (Table 2, product 8)² : prepared from *p*-anisidine (0.061g, 0.5mmol) and 1-penten-3-ol (0.172g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow solid (0.099g, 96%). ¹H NMR (400 MHz, CDCl₃) $\delta = 6.78$ (d, *J*=8.8, 2H), 6.59 (d, *J*=8.8, 2H), 3.74 (s, 3H), 3.37 (t, *J*=6.1, 2H), 2.71 (t, *J*=6.1, 2H), 2.44 (q, *J* = 7.3, 2H), 1.05 (t, *J*=7.3, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 211.04, 152.50, 141.93, 115.02, 114.77, 55.87, 41.40, 39.85, 36.41, 7.77. HRMS (ESI): calculated for C₁₂H₁₇NO₂ ([M + H]⁺) : 208.1332, found : 208.1349.

1-((2-methoxyphenyl)amino)pentan-3-one (Table 2, product 9) : prepared from *o*-anisidine (0.061g, 0.5 mmol) and 1-penten-3-ol (0.172g, 2.0 mmol). After purification by column chromatography, the product was isolated as brown liquid (0.098g, 95%). ¹H NMR (400 MHz, CDCl₃) $\delta = 6.87$ (t, *J*=8.1, 1H), 6.77 (d, *J*=7.9, 1H), 6.71 – 6.60 (m, 2H), 3.83 (s, 3H), 3.45 (t, *J*=6.4, 2H), 2.75 (t, *J*=6.4, 2H), 2.45 (q, *J*=7.3, 2H), 1.06 (t, *J*=7.3, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 210.55, 147.13, 137.71, 121.26, 116.76, 109.88, 109.59, 55.42, 41.61, 38.32, 36.35, 7.70. HRMS (ESI): calculated for C₁₂H₁₇NO₂ ([M+Na]⁺): 230.1151, found: 230.1166

1-(phenylamino)pentan-3-one (Table 2, product 10)³ : prepared from aniline (0.046g, 0.5 mmol) and 1-penten-3-ol (0.1722g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow liquid (0.073g, 83%). ¹H NMR (700 MHz, CDCl₃) δ 7.18 (t, J = 7.8 Hz, 2H), 6.71 (t, J = 7.2 Hz, 1H), 6.62 (d, J = 7.7 Hz, 2H), 3.43 (t, J = 6.1 Hz, 2H), 2.73 (t, J = 5.9 Hz, 2H), 2.44 (q, J = 7.3 Hz, 2H), 1.06 (t, J = 7.3 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 210.97, 129.45, 117.80, 113.22, 41.40, 38.81, 36.47, 7.80. HRMS (ESI): calculated for C₁₁H₁₅NO ([M + H]⁺) : 178.1226, found : 178.1253

1-(p-tolylamino)pentan-3-one (Table 2, product 11)³ : prepared from *p*-toluidine (0.053g, 0.5 mmol) and 1-penten-3-ol(0.1722g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow solid (0.083g, 87%). ¹H NMR (700 MHz, CDCl₃) δ = 6.99 (d, *J*=8.1, 2H), 6.57 (d, *J*=8.4, 2H), 3.40 (t, *J*=6.2, 2H), 2.72 (t, *J*=6.2, 2H), 2.43 (q, *J*=7.3, 2H), 2.24 (s, 3H), 1.05 (t, *J*=7.3, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 211.02, 145.18, 129.94, 127.42, 113.72, 41.33, 39.33, 36.44, 20.52, 7.78. HRMS (ESI): calculated for C₁₂H₁₇NO ([M + H]⁺) : 192.1383, found : 192.1382

1-(o-tolylamino)pentan-3-one (Table 2, product 12)⁴ : prepared from *o*- toluidine (0.053g, 0.5 mmol) and 1-penten-3-ol (0.1722g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow liquid (0.087g, 91%). ¹H NMR (700 MHz, CDCl₃) δ = 7.13 (t, *J*=7.7, 1H), 7.06 (d, *J*=7.3, 1H), 6.67 (t, *J*=7.3, 1H), 6.63 (d, *J*=8.0, 1H), 3.48 (t, *J*=6.2, 2H), 2.76 (t, *J*=6.2, 2H), 2.45 (q, *J*=7.3, 2H), 2.12 (s, 3H), 1.07 (t, *J*=7.3, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 211.14, 145.75, 130.35, 127.18, 122.68, 117.28, 109.79, 41.33, 38.63, 36.46, 17.55, 7.76. HRMS (ESI): C₁₂H₁₇NO ([M+Na]⁺): 214.1202, found: 214.1205.

1-((4-(trifluoromethyl)phenyl)amino)pentan-3-one (Table 2, product 13) : prepared from 4-(trifluoromethyl)aniline (0.080g, 0.5 mmol) and 1-penten-3-ol (0.1722g, 2.0 mmol). After purification by column chromatography, the product was isolated as brown solid (0.116g, 95%). ¹H NMR (700 MHz, Chloroform-*d*) δ = 7.40 (d, *J*=8.5, 2H), 6.62 (d, *J*=8.5, 2H), 3.46 (t, *J*=6.1, 2H), 2.74 (t, *J*=6.0, 2H), 2.50 – 2.38 (m, 2H), 1.06 (t, *J*=7.3, 3H)⁻¹⁹F decoupled ¹³C NMR (101 MHz, CDCl₃) δ 210.73, 150.34, 126.77, 118.97, 112.03, 40.99, 38.01, 36.45, 7.72. HRMS (ESI): calculated for C₁₂H₁₄F₃NO ([M + H]⁺) : 246.1100, found : 246.1100.

1-((4-fluorophenyl)amino)pentan-3-one (Table 2, product 14)⁵ : prepared from 4-fluoroaniline (0.055g, 0.5 mmol) and 1-penten-3-ol (0.1722g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow solid (0.079g, 81%). ¹H NMR (700 MHz, CDCl₃) δ = 6.88 (m, 2H), 6.57 – 6.51 (m, 2H), 3.89 (s, 1H), 3.37 (t, *J*=6.1, 2H), 2.71 (t, *J*=6.1, 2H), 2.44 (q, *J*=7.3, 2H), 1.06 (t, *J*=7.3, 3H). ¹⁹F decoupled ¹³C NMR (101 MHz, CDCl₃) δ 211.01, 144.18, 115.85, 114.19, 41.24, 39.44, 36.48, 7.79. HRMS (ESI): calculated for C₁₁H₁₄FNO ([M + H]⁺) : 196.1132, found : 196.1159.

1-((4-methoxyphenyl)amino)hexan-3-one (Table 2, product 15) : prepared from *p*-anisidine (0.061g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as brown liquid (0.07g, 64%). ¹H NMR (700 MHz, CDCl₃) $\delta = 6.78$ (d, *J*=8.8, 2H), 6.63 (d, *J*=8.4, 2H), 3.75 (s, 3H), 3.37 (t, *J*=6.2, 2H), 2.71 (t, *J*=5.9, 2H), 2.39 (t, *J*=7.3, 2H), 1.60 (h, *J*=7.4, 2H), 0.90 (t, *J*=7.4, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 210.64, 152.83, 141.47, 115.18, 115.07, 55.92, 45.24, 41.67, 40.15, 17.31, 13.84. HRMS (ESI): calculated for C₁₃H₁₉NO₂ ([M + H]⁺) : 222.1489, found : 222.1494

1-((2-methoxyphenyl)amino)hexan-3-one (Table 2, product 16) : prepared from o-anisidine (0.061g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow liquid (0.064g, 58%). ¹H NMR (400 MHz, CDCl₃) δ 6.87 (t, *J* = 7.6 Hz, 1H), 6.77 (d, *J* = 7.0 Hz, 1H), 6.68 (t, *J* = 7.7 Hz, 1H), 6.64 (d, *J* = 7.8 Hz, 1H), 3.83 (s, 3H), 3.44 (t, *J* = 6.4 Hz, 2H), 2.74 (t, *J* = 6.3 Hz, 2H), 2.40 (t, *J* = 7.3 Hz, 2H), 1.61 (sextet, *J* = 7.4 Hz, 2H), 0.92 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 210.21, 147.19, 137.72, 121.30, 116.83, 109.97, 109.63, 55.46, 45.20, 42.00, 38.33, 17.23, 13.77. HRMS (ESI): calculated for C₁₃H₁₉NO₂ ([M + H]⁺) : 222.1489, found : 222.1499

1-(methyl(phenyl)amino)hexan-3-one (Table 2, product 17)⁶ : prepared from N-methylaniline (0.053g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow liquid (0.078g, 76%). ¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.19 (m, 2H), 6.76 – 6.68 (m, 3H), 3.64 (t, *J* = 7.0 Hz, 2H), 2.92 (s, 3H), 2.67 (t, *J* = 7.0 Hz, 2H), 2.38 (t, *J* = 7.3 Hz, 2H), 1.59 (sextet, *J* = 7.3 Hz, 2H), 0.90 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 210.42, 148.67, 129.40, 116.94, 112.61, 47.66, 45.60, 39.43, 38.72, 17.25, 13.82. HRMS (ESI): Calculated for C₁₃H₁₉NO ([M+H]⁺): 206.1539, found: 206.1553

1-((2-methoxy-4-nitrophenyl)amino)hexan-3-one (Table 2, product 18) : prepared from 2methoxy-4-nitroaniline (0.084g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow solid (0.11g, 83%). ¹H NMR (700 MHz, CDCl₃) δ 7.90 (d, *J* = 8.9 Hz, 1H), 7.61 (s, 1H), 6.54 (d, *J* = 8.9 Hz, 1H), 3.91 (s, 3H), 3.54 (t, *J* = 6.2 Hz, 2H), 2.77 (t, *J* = 6.2 Hz, 2H), 2.42 (t, *J* = 7.3 Hz, 2H), 1.62 (sextet, *J* = 7.4 Hz, 2H), 0.91 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 209.56, 145.65, 143.54, 137.64, 119.91, 106.87, 105.01, 77.34, 77.16, 76.98, 56.06, 45.26, 41.33, 37.76, 17.29, 13.80. HRMS (ESI): calculated for C₁₃H₁₈N₂O₄ ([M + Na]⁺) : 289.1159, found : 289.1187

1-((4-chlorophenyl)amino)hexan-3-one (Table 2, product 19) : prepared from 4-chloroaniline (0.063g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow solid (0.08g, 71%). ¹H NMR (400 MHz, CDCl₃) δ 7.13 (d, *J* = 8.8 Hz, 2H), 6.60 (d, *J* = 8.8 Hz, 2H), 3.39 (t, *J* = 6.1 Hz, 2H), 2.72 (t, *J* = 6.1 Hz, 2H), 2.39 (t, *J* = 7.3 Hz, 2H), 1.60 (sextet, *J* = 7.4 Hz, 2H), 0.90 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 210.28, 145.51, 129.35, 115.06, 45.25, 41.26, 39.45, 17.30, 13.82. HRMS (ESI): calculated for C₁₂H₁₆ClNO ([M + Na]⁺) : 248.0813, found : 248.0818

1-((2-chlorophenyl)amino)hexan-3-one (Table 2, product 20) : prepared from 2-chloroaniline (0.063g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as yellow liquid (0.095g, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.24 (d, *J* = 7.8 Hz, 1H), 7.14 (t, *J* = 7.7 Hz, 1H), 6.68 (d, *J* = 8.1 Hz, 1H), 6.63 (t, *J* = 7.6 Hz, 1H), 3.48 (t, *J* = 6.4 Hz, 2H), 2.74 (t, *J* = 6.4 Hz, 2H), 2.40 (t, *J* = 7.3 Hz, 2H), 1.61 (sextet, *J* = 7.5 Hz, 2H), 0.91 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃)

δ 209.96, 143.66, 129.40, 127.90, 119.68, 117.60, 111.33, 45.33, 41.74, 38.37, 17.29, 13.81. HRMS (ESI): calculated for C₁₂H₁₆ClNO ([M + Na]⁺) : 248.0813, found : 248.0814

1-((4-bromo-2-nitrophenyl)amino)hexan-3-one (Table 2, product 21) : prepared from 4-bromo-2-nitroaniline (0.108g, 0.5mmol) and 1-hexen-3-ol (0.2g, 2.0 mmol). After purification by column chromatography, the product was isolated as orange solid (0.072g, 45%). ¹H NMR (400 MHz, CDCl₃) δ 8.30 (s, 1H), 7.50 (d, *J* = 9.1 Hz, 1H), 6.79 (d, *J* = 9.2 Hz, 1H), 3.59 (m, 2H), 2.81 (t, *J* = 6.6 Hz, 2H), 2.44 (t, *J* = 7.3 Hz, 2H), 1.63 (dq, *J* = 14.7, 7.1 Hz, 3H), 0.92 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 208.65, 144.16, 139.14, 132.52, 129.15, 115.39, 106.75, 45.31, 41.51, 37.65, 17.29, 13.81. HRMS (ESI): calculated for C₁₂H₁₅BrN₂O₃ ([M+H]⁺): 315.0339, found: 315.0353



Figure S2: ¹³C NMR spectrum of spectrum of product 1



Figure S4: ¹³C NMR spectrum of product 2









FigureS10: ¹³C NMR spectrum of product 5



Figure S12: ¹³C NMR spectrum of product 6

Figure S14: ¹³C NMR spectrum of product 7

Figure S16: ¹³C NMR spectrum of product 8

Figure S18: ¹³C NMR spectrum of product 9

Figure S20: ¹³C NMR spectrum of product 10

S19

Figure S24: ¹³C NMR spectrum of product 12

Figure S26: {¹⁹F}{¹H}¹³C NMR spectrum of product 13

S22

Figure S29: ¹H NMR spectrum of product 15

Figure S31: ¹H NMR spectrum of product 16

Figure S33: ¹H NMR spectrum of product 17

Figure S35: ¹H NMR spectrum of product 18

Figure S39: ¹H NMR spectrum of product 20

Figure S41: ¹H NMR spectrum of product 21

Figure S43: ¹H NMR spectrum of palladacycle II

Figure S47: ¹⁹F decoupled ¹³C NMR spectrum of palladacycle III

Figure S49: Stacking of ¹H NMR of (a) 1-penten-3-ol, (b) 1-penten-3-one, (c) 3-pentanone and (d) crude reaction mixture of 1-penten-3-ol at optimised condition after 24h

Figure S50: Stacking of ¹³C NMR of (a) 1-penten-3-ol, (b) 1-penten-3-one, (c) 3-pentanone and (d) crude reaction mixture of 1-penten-3-ol at optimised condition after 24h

Identification code	Palladacycle II	Palladacycle III
Empirical formula	$C_{46}H_{26}Cl_2F_{12}N_4Pd_2\\$	$C_{90}H_{60}F_{12}N_4O_{10}P_2Pd_2$
Formula weight	1146.41	1860.16
Temperature/K	107(10)	112.2(4)
Crystal system	trigonal	monoclinic
Space group	R-3	P21
a/Å	27.7832(6)	14.2159(5)
b/Å	27.7832(6)	19.6780(4)
c/Å	15.2098(4)	15.4208(5)
$\alpha/^{\circ}$	90	90
β/°	90	115.902(4)
$\gamma/^{\circ}$	120	90
Volume/Å ³	10167.6(5)	3880.5(2)
Z	9	2
$\rho_{calc}g/cm^3$	1.685	1.592
μ/mm^{-1}	8.294	4.948
F(000)	5076.0	1876.0
Crystal size/mm ³	0.17 imes 0.13 imes 0.12	$0.17 \times 0.13 \times 0.12$
Radiation	$CuK\alpha \ (\lambda = 1.54184)$	$CuK\alpha (\lambda = 1.54184)$
2Θ range for data collection/°	6.876 to 133.162	6.912 to 155.518
Index ranges	$-31 \le h \le 30, -33 \le k \le 34, -10 \le 1$	$-18 \le h \le 17, -24 \le k \le 24,$
	≤ 18	$-19 \le 1 \le 19$
Reflections collected	14690	52529
Independent reflections	3906 [R _{int} = 0.1140, R _{sigma} =	15378 [R _{int} = 0.0986,
	0.0687]	$R_{sigma} = 0.0708$]
Data/restraints/parameters	3906/69/325	15378/1/1084
Goodness-of-fit on F ²	1.338	1.025
Final R indexes [I>=2 σ (I)]	$R_1 = 0.1006, wR_2 = 0.2893$	R1 = 0.0922, wR2 =
		0.2250
Final R indexes [all data]	$R_1 = 0.1038, wR_2 = 0.2945$	$R_1 = 0.1108, wR_2 = 0.2359$
Largest diff. peak/hole / e Å ⁻³	2.96/-2.71	5.31/-1.68
Flack parameter		-0.025(15)

Table S1: Crystal data and structure refinement parameters for the palladacycle II & III

Figure S51. Molecular structure of palladacycle **II** (Thermal ellipsoids at 50% probability). Selected bond lengths (Å) and bond angles (°): Pd1-N2 2.039(6), Pd1-Cl1 2.322(2), Pd1-Cl1 1.985(7), N2-Pd1-Cl1 173.7(2), N2-Pd1-Cl1 80.9(3), Cl1-Pd1-Cl1 93.1(2). (CCDC No. 2373260).

Figure S52. Molecular structure of palladacycle **III** (Thermal ellipsoids at 30% probability). Selected bond lengths (Å) and bond angles (°): Pd2-N3 2.033(12), Pd2-C32 1.968(13), Pd2-O6 2.171(12), Pd2-O2 2.051(10), Pd1-O1 2.153(10), Pd1-O5 2.058(11), Pd1-N1 2.046(11), Pd1-C9 1.954(2), Pd1-Pd2 3.226(1), O2-Pd2-O6 87.7(4), O2-Pd2-C32 91.5(6), C32-Pd2-N3 80.4(6), N3-Pd2-O6 100.1(5), C9-Pd1-O5 92.6(6), O1-Pd1-O5 88.5(5), N1-Pd1-O1 98.8(5), N1-Pd1-C9 80.1(6). (CCDC No. 2373261).

References:

- 1. K. De, J. Legros, B. Crousse, D. Bonnet-Delpon, J. Org. Chem., 2009, 74, 6260.
- 2. H. W. Lam; G. J. Murray, J. D.Firth, Org. Lett. 2005, 7, 5743.
- 3. R. Jiang, D. H. Li, J. Jiang, X. P. Xu, T. Chen, S. J. Ji, Tetrahedron. 2005, 67, 3631.
- 4. A.Ying, Q. Zhang, H. Li, et al. Res. Chem. Intermed., 2013, 39, 517.
- 5. S. Kim, S. Kang, G. Kim, Y. Lee, J. Org. Chem. 2016, 81, 4048.
- 6. F. Yang, J. Li, J. Xie, J. Huang, Org. Lett. 2010, 12, 5214.